Earnings call transcript: Viveo misses Q1 2026 forecasts despite margin gains

Viveo’s Q1 2026 results missed expectations, with EPS at -0.2098 versus -0.1207 forecast and revenue of BRL 2.83 billion below the BRL 2.92 billion consensus, but gross margin improved to 15.8% and adjusted EBITDA rose 30% to BRL 208 million. The company also reported a BRL 35 million net loss, though it generated BRL 45 million in operating cash flow and reduced leverage to 3.88x. Management cited a favorable competitive backdrop, higher interest rates, inflation, and FX volatility, while the stock rose 3.97% after hours before later falling 2.52%.

Analysis

The market is rewarding the wrong part of the story if it focuses only on the headline miss. The real signal is that management is deliberately shrinking low-return activity while converting the remaining book into higher-margin, lower-working-capital business; that combination can produce a structurally better equity story even with muted top-line growth. The key second-order effect is that higher gross margin plus tighter cash conversion reduces dependence on expensive local funding, which matters more than EPS in a high-rate regime.

For the competitive set, the strongest implication is not that this company is “winning” outright, but that weaker players may be forced into a margin race they cannot fund. If selective bidding is already supporting margins in hospitals/clinics, then smaller distributors with poorer balance sheets are likely to lose share or accept uneconomic volume to preserve shelf space, which can compress returns across the channel over the next 2-4 quarters. That creates a more durable operating backdrop for the stronger incumbent, but also raises the risk of temporary share volatility as the company continues to reject volume.

The contrarian view is that the equity may be under-owned because the market is still anchored to leverage and funding fears, while the operating model is quietly de-risking. The upside case is not multiple expansion on revenue growth; it is a re-rating if cash generation stays positive through the seasonally weak first half and debt rollovers proceed smoothly. The main tail risk is that the current margin mix is partly helped by timing, FX, and portfolio pruning, so if pricing discipline loosens or inflation re-accelerates, the current improvement could flatten quickly.

For the named comps, the read-through to domestically oriented healthcare distributors is mildly positive, but it is more a signal on pricing power and capital intensity than on the sector beta itself. In a higher-for-longer rate environment, balance sheet quality is becoming the differentiator, so the market may eventually reward firms that can self-fund inventory and debt service even if reported growth stays pedestrian.

Key Decisions for Investors

• Long VVEO3 on a 3-6 month horizon only on pullbacks after any post-earnings fade; thesis is deleveraging + margin normalization, with upside from covenant relief and debt rollover, but size small because the stock remains high-volatility and execution-sensitive.
• Pair trade: long quality healthcare distributor with stronger balance sheet / shorter cash conversion, short weaker levered local distributor exposure over the next 2 quarters; the spread should widen if rates stay elevated and selective pricing continues.
• Avoid chasing the post-earnings bounce in VVEO3 after 1-2 day strength; wait for confirmation that Q2 cash generation is not simply working-capital reversal, because that is the key failure mode for the current narrative.
• If available, buy limited-risk upside in VVEO3 via 3-6 month call spreads rather than stock; the catalyst path is asymmetric if debt markets validate management’s rollover plan, while downside remains real if margin gains prove transient.
• For broader Brazil healthcare exposure, prefer businesses with pricing power and lower financing needs; this print reinforces that in high-rate environments, operating leverage matters less than funding leverage.